Damora Therapeutics: Well-Funded Moonshot For CALR Mutations
Damora Therapeutics is concentrating on developing treatments for mutant-CALR blood diseases, with its primary asset being DMR-001. The company is well-funded, boasting around $562.3 million in cash, which is expected to sustain operations until 2029. However, DMR-001 faces competition from other assets that are further along in research and development.
- ▪Damora Therapeutics is focused on mutant-CALR blood diseases.
- ▪The company has approximately $562.3 million in cash.
- ▪DMR-001 faces competition from more advanced R&D assets.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":"Stock Ideas","item":"https://seekingalpha.com/stock-ideas"},{"@type":"ListItem","position":3,"name":"Long Ideas","item":"https://seekingalpha.com/stock-ideas/long-ideas"},{"@type":"ListItem","position":4,"name":"Healthcare ","item":"https://seekingalpha.com/stock-ideas/healthcare"}]}{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4909103-damora-therapeutics-well-funded-moonshot-for-calr-mutations"},"author":{"@type":"Person","name":"Myriam…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
